These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 30642285)

  • 1. Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome.
    Romine PE; Martins RG; Eaton KD; Wood DE; Behnia F; Goulart BHL; Mulligan MS; Wallace SG; Kell E; Bauman JE; Patel SA; Vesselle HJ
    BMC Cancer; 2019 Jan; 19(1):70. PubMed ID: 30642285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial.
    Chaft JE; Dunphy M; Naidoo J; Travis WD; Hellmann M; Woo K; Downey R; Rusch V; Ginsberg MS; Azzoli CG; Kris MG
    J Thorac Oncol; 2016 Apr; 11(4):537-44. PubMed ID: 26724474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer.
    Pöttgen C; Gauler T; Bellendorf A; Guberina M; Bockisch A; Schwenzer N; Heinzelmann F; Cordes S; Schuler MH; Welter S; Stamatis G; Friedel G; Darwiche K; Jöckel KH; Eberhardt W; Stuschke M
    J Clin Oncol; 2016 Jul; 34(21):2526-33. PubMed ID: 27247220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
    Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Langen HJ; Bares R
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):463-71. PubMed ID: 17103167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
    Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E
    Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography as a predictor of response in locally advanced non-small-cell carcinoma of the lung.
    Roy S; Pathy S; Kumar R; Mohanti BK; Raina V; Jaiswal A; Taywade S; Garg K; Thulkar S; Mohan A; Mathur S; Behera D
    Nucl Med Commun; 2016 Feb; 37(2):129-38. PubMed ID: 26544097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
    de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
    Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
    J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.
    Ryu JS; Choi NC; Fischman AJ; Lynch TJ; Mathisen DJ
    Lung Cancer; 2002 Feb; 35(2):179-87. PubMed ID: 11804691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer.
    Tanvetyanon T; Eikman EA; Sommers E; Robinson L; Boulware D; Bepler G
    J Clin Oncol; 2008 Oct; 26(28):4610-6. PubMed ID: 18824709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).
    Kocher F; Pircher A; Mohn-Staudner A; Romeder F; Duller W; Steinmaurer M; Eckmayr J; Schmid T; Hilbe W; Fiegl M; Greil R
    Lung Cancer; 2014 Sep; 85(3):395-400. PubMed ID: 25043642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
    AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).
    Agarwal M; Brahmanday G; Bajaj SK; Ravikrishnan KP; Wong CY
    Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):691-8. PubMed ID: 19915840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment].
    Schmücking M; Baum RP; Bonnet R; Junker K; Müller KM
    Pathologe; 2005 May; 26(3):178-89. PubMed ID: 15800765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.
    Kremer R; Peysakhovich Y; Dan LF; Guralnik L; Kagna O; Nir RR; Bar-Shalom R
    Ann Nucl Med; 2016 Feb; 30(2):114-21. PubMed ID: 26613715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and predictive role of [
    Zucali PA; Lopci E; Ceresoli GL; Giordano L; Perrino M; Ciocia G; Gianoncelli L; Lorenzi E; Simonelli M; De Vincenzo F; Setti LR; Bonifacio C; Bonomi M; Bombardieri E; Chiti A; Santoro A
    Cancer Med; 2017 Oct; 6(10):2287-2296. PubMed ID: 28941158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
    Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
    Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The utility of
    Guo R; Yan W; Wang F; Su H; Meng X; Xie Q; Zhao W; Yang Z; Li N
    Cancer Imaging; 2024 Sep; 24(1):120. PubMed ID: 39256860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.